Joseph Stringer

“One on HDV, where do you peg the current U.S. HDV diagnosis rate today? And I suppose now that there's an approved therapy plus some momentum toward universal testing in the guidelines, where do you think diagnosis rates could realistically plateau and over what time frame?”

“I was wondering if you can, like, maybe cover, like, maybe, like, historical benchmarks or, like, you know, endpoints that you're going to be looking at as you run this trial. and as well as maybe if you can describe, like, how much incremental cost it's going to add to your expenses.”

“For the Phase III Eclipse I trial on HDV, what's your current thinking on the bar for success on the response rates on the 48-week primary composite endpoint? Would, replicating the 38% or so response rates that you saw in Phase II set you up for success here?”

“Just to follow up on a previous answer you gave on the primary care setting, I know this is part of your future expansion plans, but just curious if you have any early quantitative metrics on the patients that cycle from primary care through a specialist back to primary care, for example, what's the recapture rate…”

“I just wanted to follow up on the previous question, looking at the IQVIA prescription data and the impact of seasonality. Is the magnitude of the seasonality effect this cycle in line with your expectations, I guess, all things considered?”